4884 — Kringle Pharma Share Price
0.000.00%
Last trade - 00:00- ¥6bn
- ¥4bn
- ¥80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.96 | ||
| Price to Tang. Book | 2.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 70.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.58% | ||
| Return on Equity | -37.54% | ||
| Operating Margin | -1083.5% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 467.62 | 289.76 | 391.83 | 69.25 | 80.04 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kringle Pharma Inc is a Japan-based company mainly engaged in the development of pharmaceuticals. The Company is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The Company is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.
Directors
- Kiichi Adachi PRE (54)
- Yutaka Matsuura OTH (52)
- Etsuro Hashimura OTH (69)
- Koichi Murakami OTH
- Akihiro Tomoyasu DRC (50)
- Masato Fukui IND (44)
- Koichiro Yoshino IND (72)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 21st, 2001
- Public Since
- December 28th, 2020
- No. of Shareholders
- 4,033
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 6,837,064
- Address
- 207, IBARAKI-SHI, 567-0085
- Web
- https://www.kringle-pharma.com/
- Phone
- +81 726418739
- Auditors
- Ernst & Young ShinNihon LLC
Upcoming Events for 4884
Dividend For 4884.T - 0.0000 JPY
Similar to 4884
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the Kringle Pharma share price?
As of Today at 21:38 UTC, shares in Kringle Pharma are trading at ¥822. This share price information is delayed by 15 minutes.
How has the Kringle Pharma share price performed this year?
Shares in Kringle Pharma last closed at ¥822 and the price had moved by +45.74% over the past 365 days. In terms of relative price strength the Kringle Pharma share price has outperformed the Nikkei 225 Index by +53.59% over the past year.
What are the analyst and broker recommendations for Kringle Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Kringle Pharma dividend yield?
Kringle Pharma does not currently pay a dividend.
Does Kringle Pharma pay a dividend?
Kringle Pharma does not currently pay a dividend.
When does Kringle Pharma next pay dividends?
Kringle Pharma does not currently pay a dividend.
How do I buy Kringle Pharma shares?
To buy shares in Kringle Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kringle Pharma?
As of the previous close price of ¥822, shares in Kringle Pharma had a market capitalisation of ¥6bn.
Where are Kringle Pharma shares listed?
Here are the trading details for Kringle Pharma:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4884
What kind of share is Kringle Pharma?
Based on an overall assessment of its quality, value and momentum Kringle Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kringle Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Kringle Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kringle Pharma. Over the past six months, its share price has outperformed the Nikkei 225 Index by +14.24%.
As of the last closing price of ¥822, shares in Kringle Pharma were trading -7.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kringle Pharma PE Ratio?
The Kringle Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥822.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kringle Pharma?
Kringle Pharma's management team is headed by:
- Kiichi Adachi - PRE
- Yutaka Matsuura - OTH
- Etsuro Hashimura - OTH
- Koichi Murakami - OTH
- Akihiro Tomoyasu - DRC
- Masato Fukui - IND
- Koichiro Yoshino - IND